*NEWS: Urovant Sciences Announces It Will Receive Loan to Enable It to Continue Seeking FDA Approval for its Lead Drug Therapy, Vibegron. Urovant is a Biopharma Startup Focused on Developing and Commercializing Therapies for Urologic Conditions…
This alliance is significant because it will include the transfer from Roivant Sciences to Sumitomo Dainippon Pharma of all of Roivant’s ownership interests in Urovant Sciences, according to a press release issued by Urovant on October 31. Other significant aspects include: - Sumitomo
*NEWS: Novartis Confirmation of Alcon Spinoff Happens to Coincide with OCTANe’s Ophthalmology Technology Summit. Alcon Says Will Keep Manufacturing and BD&L in OC.
OCTANe’s annual 2018 Ophthalmology Technology Summit on June 29 coincided with the national news that Novartis will definitely spin off Alcon – with a presence in Lake Forest - to shareholders and buy back up to $5 billion in stock,